Clinical Trials Browser

Chondrosarcoma × CNS × 1 year × Clear all

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT04087902 2026-05-20

Long-Term Longitudinal QoL in Patients Undergoing EEA

Chondrosarcoma, Chordoma, Craniopharyngioma, Encephalocele, Meningioma, Pituitary Neoplasms, Esthesioneuroblastoma, Olfactory, Central Nervous System Cysts

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Phase 1 Completed

174 enrolled

CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT06645808 2025-12-29

VARTUTRACE

Phase EARLY_PHASE1 Recruiting

32 enrolled

BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Osteosarcoma, Stomach Neoplasms

Clinical Trials

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

Long-Term Longitudinal QoL in Patients Undergoing EEA

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

VARTUTRACE